Other News To Note

 Ligand Pharmaceuticals Inc., of San Diego, and Pfizer Inc., of New York, said the FDA accepted for review a new drug application for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms and vulvar and vaginal atrophy associated with menopause, as well as the prevention of postmenopausal osteoporosis.